Research Paper Volume 9, Issue 10 pp 2098—2116

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis

class="figure-viewer-img"

Figure 10. A short c-Myc-related mitochondrial signature predicts poor clinical outcome, in both ER(+) and ER(-) breast cancer patients. Note that this short 3-gene signature (HSPD1/COX5B/TIMM44) also effectively predicts tumor recurrence in larger populations of both ER(+) [N=3,082] and ER(-) [N=618] breast cancer patients. RFS, recurrence-free survival.